Objective To investigate the value of the application of dapagliflozin combined with irbesartan in the blood glucose control of diabetic nephropathy.Methods Seventy-eight patients with diabetic nephropathy admitted to Shouzhan Branch of Fuzhou Changle District General Hospital from May 2021 to May 2023 were randomly selected as the study objects,and they were divided into the reference group(n=39,irbesartan combined with metformin)and the observation group(n=39,irbesartan combined with dapagliflozin)by envelope method.The clinical efficacy,blood glu-cose control,renal function and adverse reactions were compared between the two groups.Results The total effective rate of observation group(94.87%)was higher than that of reference group(79.49%),and the difference was statisti-cally significant(χ2=4.129,P<0.05).There were no statistically significant differences in blood glucose control and re-nal function indexes between the two groups before treatment(both P>0.05).After 3 months of treatment,the blood glucose control and renal function indexes of the observation group were better than those of the reference group,and the differences were statistically significant(both P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups after treatment(χ2=0.214,P>0.05).Conclusion In the blood glucose control of diabetic nephropathy,the combination of irbesartan and dapagliflozinn can improve clinical efficacy,effectively con-trol blood glucose level,improve renal function,and not increase the risk of adverse reactions.
NETL
NSTL
万方数据
